Pharming announces enrolment of first patient in multinational clinical trial for the treatment of COVID-19 with RUCONEST®
Pharming Group N.V. announces that the first patient has been enrolled in a randomized, controlled, investigator-initiated clinical trial in up to 150 patients for the treatment with RUCONEST® (recombinant human C1 inhibitor) of patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalized with related severe pneumonia at the University Hospital Basel in Basel, Switzerland.
- Clinical trial follows encouraging results from five patients with confirmed COVID-19 infections administered RUCONEST® to treat the related severe pneumonia
- First patient at the University Hospital Basel, Basel, Switzerland, with confirmed COVID-19 infection has been enrolled in a clinical trial to investigate the use of RUCONEST® to prevent severe SARS-CoV-2 infection in hospitalised patients with COVID-19
- Study to be extended to additional clinical centres in Switzerland, Mexico and Brazil
- Additional study in multiple centres in the US in final stages of preparation
RUCONEST®’s multiple interactions with key inflammation pathways therefore make it a promising candidate to prevent the severe complications observed in COVID-19 patients.- Bruno Giannetti - CMO
Would you like to switch to another language? Click here to visit our English website.